Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials

References

• SabattiniEBacciFSagramosoCPileriSAWHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overviewPathologica20101023838721171509
   PubMedGoogle Scholar
• HarousseauJLMoreauPAutologous hematopoietic stem-cell transplantation for multiple myelomaN Engl J Med2009360252645265419535803
   PubMed Web of Science ®Google Scholar
• SchaarCGKluin-NelemansHCTe MarveldeCInterferon-alpha as maintenance therapy in patients with multiple myelomaAnn Oncol200516463463915741226
   PubMed Web of Science ®Google Scholar
• ChouTTobinaiKUikeNMelphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112Jpn J Clin Oncol201141458658921247967
   PubMed Web of Science ®Google Scholar
• BerensonJRCrowleyJJGroganTMMaintenance therapy with alternate-day prednisone improves survival in multiple myeloma patientsBlood20029993163316811964279
   PubMed Web of Science ®Google Scholar
• MorganGJGregoryWMDaviesFEThe role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisBlood2012119171522021371
   PubMed Web of Science ®Google Scholar
• PalumboAGayFFalcoPBortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patientsJ Clin Oncol201028580080720048187
   PubMed Web of Science ®Google Scholar
• YeXHuangJPanQMaintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trialsPLoS One201388e7263523977334
   PubMed Web of Science ®Google Scholar
• ClaveEDouayCComanTLenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasisLeuk Lymphoma20145581788179524237448
   PubMed Web of Science ®Google Scholar
• RichardsonPGHideshimaTAndersonKCBortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancersCancer Control200310536136914581890
   PubMedGoogle Scholar
• MellqvistUHGimsingPHjertnerOBortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized Phase 3 trialBlood2013121234647465423616624
   PubMed Web of Science ®Google Scholar
• CavoMPantaniLPetrucciMTBortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaBlood2012120191922498745
   PubMed Web of Science ®Google Scholar
• SonneveldPSchmidt-WolfIGvan der HoltBBortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized Phase III HOVON-65/GMMG-HD4 trialJ Clin Oncol201230242946295522802322
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• DuvalSTweedieRTrim and Fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysisBiometrics200056245546310877304
   PubMed Web of Science ®Google Scholar
• DuvalSTweedieRA nonparametric “Trim and Fill” method of accounting for publication bias in meta-analysisJ Am Stat Assoc200095449899810.1080/01621459.2000.10473905
   Web of Science ®Google Scholar
• GarderetLIacobelliSMoreauPSuperiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working arty of the European Group for Blood and Marrow TransplantationJ Clin Oncol201230202475248222585692
   PubMed Web of Science ®Google Scholar
• ScheidCSonneveldPSchmidt-WolfIGBortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialHaematologica201499114815423996482
   PubMed Web of Science ®Google Scholar
• RosinolLOriolATeruelAISuperiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized Phase 3 PETHEMA/GEM studyBlood201212081589159622791289
   PubMed Web of Science ®Google Scholar
• KimHJYoonSSLeeDSSequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a Phase II trialAnn Hematol201291224925621789621
   PubMed Web of Science ®Google Scholar
• NebenKLokhorstHMJauchAAdministration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pBlood2012119494094822160383
   PubMed Web of Science ®Google Scholar
• CavoMTacchettiPPatriarcaFBortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3 studyLancet201037697582075208521146205
   PubMed Web of Science ®Google Scholar
• PalumboAMinaRCerratoCRole of consolidation/maintenance therapy in multiple myelomaClin Lymphoma Myeloma Leuk201313Suppl 2S349S35424290220
   PubMedGoogle Scholar
• CavoMBrioliATacchettiPRole of consolidation therapy in transplant eligible multiple myeloma patientsSemin Oncol201340561061724135406
   PubMed Web of Science ®Google Scholar
• SonneveldPGoldschmidtHRosiñolLBortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of Phase III randomized, controlled trialsJ Clin Oncol201331263279328723897961
   PubMed Web of Science ®Google Scholar
• DimopoulosMAChenCSpencerALong-term follow-up on overall survival from the MM-009 and MM-010 Phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia200923112147215219626046
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWReversibility of symptomatic peripheral neuropathy with bortezomib in the Phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelineBr J Haematol2009144689590319170677
   PubMed Web of Science ®Google Scholar
• WangYAiLCuiGOnce- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myelomaJ Huazhong Univ Sci Technolog Med Sci201232449550022886960
   PubMedGoogle Scholar
• MoreauPKaramaneshtIIDomnikovaNPharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myelomaClin Pharmacokinet2012511282382923018466
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• LonialSAndersonKCAssociation of response endpoints with survival outcomes in multiple myelomaLeukemia201428225826823868105
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAAGiraltSImportance of achieving a complete response in multiple myeloma, and the impact of novel agentsJ Clin Oncol201028152612262420385994
   PubMed Web of Science ®Google Scholar
• van de VeldeHJLiuXChenGComplete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myelomaHaematologica200792101399140618024376
   PubMed Web of Science ®Google Scholar
• BiranNJagannathSChariARisk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapiesClin Adv Hematol Oncol201311957858324518521
   PubMedGoogle Scholar
• Avet-LoiseauHLeleuXRousselMBortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)J Clin Oncol201028304630463420644101
   PubMed Web of Science ®Google Scholar